Friday fantasies

Around the weblogs. The MARQUES Class 46 blog mentions a call from the International Chambers of Commerce (ICC) for an industrial self-regulation scheme for reducing misleading and brand-damaging advertisements from the digital advertising ecosystem; picking up on this, the MARQUES LinkedIn Group wonders how relevant the ICC is: opinions are welcomed. The 1709 Blog's latest sidebar poll, on protecting works by subject-matter categories, has got off to a slow start, but it's open till 6 April so you're not too late to participate. Another blog that has just been drawn to the IPKat's attention belongs to Ideas Matter, which is a consortium of cross-sector enterprises that seeks to promote the benefits of intellectual property: you can see a list of members, here, which gives a fairly good idea of what you might expect to find in it.

Fakes in Italy: good news.  From the IPKat's friends at Modiano & Partners comes news via the Italian Ministry of Economic Development that new members have now been appointed to the National Anti-Counterfeiting Council (CNAC), which includes representatives of law enforcement, producers, consumer groups and no fewer than 11 Ministers. This Kat learns that the CNAC can be an effective tool, in that it is a single body combining all the forces that combat the serious problem of counterfeiting every day. Its duties are based on an Anti-Counterfeiting Plan that was agreed at the Italian Convention on the Fight against Counterfeiting. Good news, though Merpel warns that there have been many instances of good news in the fight against counterfeiting, but they are often like waves in the sea which, while apparently huge when viewed from the distance, are no more than ripples by the time they reach the shore.

Fire in the blood. From London-based IP scholar Siva Thambisetty comes news of a free film screening of 'Fire in the Blood' next Thursday, 20 March 2014, in the Sheikh Zayed Theatre, New Academic Building, LSE. Doors open at 6 pm and the screening is from 7.30 pm – 8.15 pm, followed by a question and answer session with Chairman of Cipla, Dr Yusuf Hamied. Says Siva, this event is free and open to all with no ticket required Entry is on a first come, first served basis: for any queries email or call +44 20 7955 7687. 
The film is described as "an intricate tale of 'medicine, monopoly and malice', ... of how Western pharmaceutical companies and governments aggressively blocked access to low-cost AIDS drugs for the countries of Africa and the global south in the years after 1996 -- causing ten million or more unnecessary deaths – and the improbable group of people who decided to fight back. Shot on four continents and including contributions from global figures such as Bill Clinton, Desmond Tutu and Joseph Stiglitz, Fire in the Blood is the never-before-told true story of the remarkable coalition which came together to stop 'the Crime of the Century' and save millions of lives in the process. As the film makes clear, however, this story is by no means over. With dramatic past victories having given way to serious setbacks engineered far from public view, the real fight for access to life-saving medicine is almost certainly just beginning".
This Kat, who has not seen the film, is curious to know what readers of this weblog think of it.

Enjoy the agreeable intimacy of a round table. There's an INTA Europe Roundtable on Trade Mark Licensing coming up soon, on Thursday 3 April 2014 in the Amsterdam office of Simmons & Simmons. It will run from 14:30 – 17:30 pm, followed by drinks in the host firm's bar).  This event claims that "attendees will be taught how to draft trade mark licence agreements" and the Roundtable will be led by Willem Wiggers (founder of WeAgree, a company specialised in accelerated contract drafting), Michael Gavey and Class 99 blogger Hidde Koenraad (both of Simmons & Simmons)  There is no admission fee, but you've got to register first. Details are available here.
Friday fantasies Friday fantasies Reviewed by Jeremy on Friday, March 14, 2014 Rating: 5


  1. I'd have thought readers of this blog had an IQ greater than that of a chipmunk and would therefore not waste their time on such a film.

    Can anyone remind me how many new medicines Cipla, for example, have discovered? I don't have any fingers on my hand, but it is probably enough to count with.

    I don't remember any global ban on individuals or rich nations paying a fair-market price for the drugs so that they can be gifted to the poor, or any ban on the South African government publishing truthful information on AIDS.

  2. In response to Anonymous of 10:46, the readers of this blog are capable of making up their own minds on the issue. The film is an insight into the difficult debate on pharma v those who can't afford medicines. This is a controversial area, but all parties do deserve to be heard. The film is well made and I think presents its case well.

  3. To anonymous of 10:46 - anyone with the IQ of even half a chipmunk, or indeed with half the brains of a whole chipmunk - and who was a regular reader of this blog would instantly know that the bit that reads "This Kat, who has not seen the film, is curious to know what readers of this weblog think of it" actually means "This Kat isn't going to be watching it and suggests that his pro-IP friends turn up in quantity to try to give the positive side of IP an airing in the face of the sort of anti-IP message that this film would appear to be sending out".

  4. to 1st response of my comment: I can't see how my comment could be construed in a way which reads that I don't believe readers of this blog can't make up their own minds. In fact, I'm sure I praise their intelligence rather than criticise it.

    to 2nd response: Whilst I am highly respectful of his views and his contribution to IP, I must admit that I have not put Jeremy on the list of nominations for "person most likely to be the second coming" such that I didn't expect people to cancel their Friday night down the boozer at his whim.

  5. Anonymous of 12.32:

    While it is true that Jeremy may not be the "person most likely to be the second coming", he may still be a candidate. His Facebook entry gives his date of birth as 25 December 1951.


All comments must be moderated by a member of the IPKat team before they appear on the blog. Comments will not be allowed if the contravene the IPKat policy that readers' comments should not be obscene or defamatory; they should not consist of ad hominem attacks on members of the blog team or other comment-posters and they should make a constructive contribution to the discussion of the post on which they purport to comment.

It is also the IPKat policy that comments should not be made completely anonymously, and users should use a consistent name or pseudonym (which should not itself be defamatory or obscene, or that of another real person), either in the "identity" field, or at the beginning of the comment. Current practice is to, however, allow a limited number of comments that contravene this policy, provided that the comment has a high degree of relevance and the comment chain does not become too difficult to follow.

Learn more here:

Powered by Blogger.